Home > Analytics > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 532296     NSE : GLENMARK    
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive]
Debt : High
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
Jun 14,2024
Price(EOD): ₹ 1,236.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 34,884.15 Cr
Value of ₹ 1 Lac invested in GLENMARK PHARMACEUTICALS
on Jun 18,2019 (price: ₹ 527.15)

₹ 1 L

₹ 2.34 L

1W : 4.3% 1M : 21.9% 1Y : 90.6%
COMMUNITY POLL
for GLENMARK PHARMACEUTICALS
Please provide your vote to see the results
GLENMARK PHARMACEUTICALS is part of below Screeners ↓
Best Quarterly Growth Mid Cap Stocks
Best 1M Momentum Mid Cap Stocks
Industry Peers & Returns1W1M1Y
GLENMARK PHARMACEUTICALS 4.3% 21.9% 90.6%
SUN PHARMACEUTICAL INDUSTRIES 1.4% -0.7% 53.4%
CIPLA 2.9% 12.5% 59.5%
DR REDDYS LABORATORIES -0.7% 3.4% 29.5%
ZYDUS LIFESCIENCES -0.5% 2.6% 114.2%
DIVIS LABORATORIES 2% 16.7% 31.5%
MANKIND PHARMA 3.6% 7.3% 47.1%
TORRENT PHARMACEUTICALS 1.3% 7% 58.7%
LUPIN -2% -4.3% 96.3%

FUNDAMENTAL ANALYSIS OF GLENMARK PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Mar2024, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF GLENMARK PHARMACEUTICALS

 
Valuation Score
[As on : Jun 14,2024 ]

Ratio Consolidated
P/E
P/B
P/S
-20.57
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -1,695.40 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

4.44
P/B Calculated based on Book Value of Rs 7,847.93 Cr
[Latest Year - Mar2024 - Consolidated Results ]

2.86
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 12,178.60 Cr
[Latest Qtr - Mar2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 10% undervalued companies ! Discover More →

FAIR VALUE OF GLENMARK PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
48%
39%
47%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF GLENMARK PHARMACEUTICALS


Insights 💡 GLENMARK is one of the top 42% companies with bullish price momentum currently! Discover More →

GLENMARK PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF GLENMARK PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2023
2022
2021
Avg_3yrs
0.18
0.22
0.25
0.22
0.46
0.4
0.67
0.51
[Last Annual Data : Mar2023]
Financial Ratios →

PLEDGED PROMOTER SHARES OF GLENMARK PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2023

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF GLENMARK PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
22.19%
341.72%
201.81%
-175.51%
2.08%
26.75%
177.11%
-125.42%
QtrlyTrend
4
Latest Qtr: Mar2024
Quarterly Result Analysis →


GLENMARK PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE MIDSMALLCAP 4.6% 9.7% 65.2%
S&P BSE MOMENTUM 4.5% 9.3% 80.4%
S&P BSE 400 MIDSMALLCAP 4.3% 9.7% 61.8%
S&P BSE MID CAP 4.3% 9.2% 67.2%
S&P BSE 250 SMALLCAP 4.2% 9.4% 60.7%
NSE Indices1W1M1Y
NIFTY FREE SMALL 100 4.4% 9.9% 73.1%
NIFTY MID SMALL400 4.3% 9.3% 63.1%
NIFTY SMALLCAP250 4.3% 9.4% 66.3%
NIFTY SMALLCAP 50 3.9% 10.8% 77.9%
NIFTY500 MULTICAP 50:25:25 3% 7.6% 48.1%

You may also like the below Video Courses


FAQ about GLENMARK PHARMACEUTICALS


Is GLENMARK PHARMACEUTICALS good for long term investment?

As on Jun 14,2024, the Fundamentals of GLENMARK PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of GLENMARK PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is GLENMARK PHARMACEUTICALS UnderValued or OverValued?

As on Jun 14,2024, GLENMARK PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of GLENMARK PHARMACEUTICALS ?

As on Jun 14,2024, the Intrinsic Value of GLENMARK PHARMACEUTICALS is Rs. 838.22 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 834.95
Fair Value [Median EV / Sales Model] : Rs. 892.39
Fair Value [Median Price / Sales Model] : Rs. 838.22
Estimated Median Fair Value of GLENMARK PHARMACEUTICALS : Rs. 838.22

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is GLENMARK PHARMACEUTICALS trading at a Premium or Discount?

As on Jun 14,2024, GLENMARK PHARMACEUTICALS is trading at a Premium of 47% based on the estimates of Median Intrinsic Value!